Milestone Pharmaceuticals, Inc. Stock News
$2.26
5.12%
today
Nasdaq,
Dec 30, 09:47 pm CET
Milestone Pharmaceuticals, Inc. Stock News
Neutral
GlobeNewsWire
●
about 2 months ago
NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025
Neutral
GlobeNewsWire
●
4 months ago
MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced its licensing partner, Ji Xing Pharmaceuticals Ltd, released positive topline results from a multi-center, randomized, double-blind, placebo-controlled...
Neutral
GlobeNewsWire
●
4 months ago
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors (“Board”), effective September 3, 2024.
Neutral
GlobeNewsWire
●
5 months ago
– NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 – Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 – Stuart Duty and Andrew Saik Appointed as Independent Board Directors MONTREAL and CHARLOTTE, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the second quarter e...
Positive
24/7 Wall Street
●
5 months ago
Are you looking for stocks to buy with low price tags?
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
